Legislation

Title: Public Health - Gabapentin - Monitoring by Prescription Drug Monitoring Program and Report
Sponsored by: Delegate Kipke
Status: In the House - Withdrawn by Sponsor
Analysis: Fiscal and Policy Note

Synopsis

Requiring the Prescription Drug Monitoring Program to monitor the prescribing and dispensing of Gabapentin by all prescribers and dispensers in the State; and requiring the Maryland Department of Health to submit a report on whether Gabapentin should be added to the a controlled dangerous substances schedule to the Senate Finance Committee and the House Health and Government Operations Committee on or before December 31, 2019.

Committees

Original:: Health and Government Operations Click to view Recorded Media

Details

Bill File Type: Regular

Effective Date(s): June 1, 2019

History

Legislation History
Chamber House Calendar Date 2/08/2019 Legislative Date 2/08/2019 Action First Reading Health and Government Operations Proceedings
Chamber Calendar Date Legislative Date Action Text - First - Public Health - Gabapentin - Monitoring by Prescription Drug Monitoring Program and Report Proceedings
Chamber House Calendar Date 2/13/2019 Legislative Date 2/13/2019 Action Hearing 2/27 at 1:00 p.m. Proceedings
Chamber Calendar Date Legislative Date Action Vote - House - Committee - Health and Government Operations Proceedings Click to view Recorded Media
Chamber House Calendar Date 4/04/2019 Legislative Date 4/04/2019 Action Withdrawn by Sponsor Proceedings

Chamber	Calendar Date	Legislative Date	Action	Proceedings
House	2/08/2019	2/08/2019	First Reading Health and Government Operations
			Text - First - Public Health - Gabapentin - Monitoring by Prescription Drug Monitoring Program and Report
House	2/13/2019	2/13/2019	Hearing 2/27 at 1:00 p.m.
			Vote - House - Committee - Health and Government Operations	Click to view Recorded Media
House	4/04/2019	4/04/2019	Withdrawn by Sponsor

File Code

Subjects

Statutes